Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Mayo's Cancer Dx; OGT's Cancer Panel; Natera's Panorama

Premium

The Mayo Clinic has launched CANCP, a 50-gene cancer panel that assesses hotspot mutations using next-generation sequencing with the goal of predicting a patient's response to therapy. The test is available to Mayo patients and providers worldwide through Mayo Medical Laboratories.


Oxford Gene Technology has launched SureSeq Solid Tumor Panel, a 60-gene cancer panel that uses hybridization-based enrichment and is assessed via next-generation sequencing. The panel was validated on formalin-fixed paraffin embedded tissue and covers the entire exons of the 60 genes.


Natera has received conditional approval from the New York State Department of Health to use its next-generation sequencing-based, noninvasive prenatal test, Panorma, to test for chromosomal aneuploidies and DiGeorge syndrome in all pregnant women.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.